Ocugen, Inc.

BUL:2H51 Stock Report

Market Cap: €234.1m

Ocugen Management

Management criteria checks 2/4

Ocugen's CEO is Shankar Musunuri, appointed in Sep 2019, has a tenure of 4.42 years. total yearly compensation is $7.66M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth €1.88M. The average tenure of the management team and the board of directors is 1.4 years and 4.3 years respectively.

Key information

Shankar Musunuri

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage9.3%
CEO tenure4.4yrs
CEO ownership0.8%
Management average tenure1.4yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Shankar Musunuri's remuneration changed compared to Ocugen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$76m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$80m

Dec 31 2022US$8mUS$715k

-US$81m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$8mUS$541k

-US$58m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$2mUS$500k

-US$34m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$572kUS$420k

-US$20m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$431kUS$420k

-US$18m

Compensation vs Market: Shankar's total compensation ($USD7.66M) is above average for companies of similar size in the BG market ($USD566.05K).

Compensation vs Earnings: Shankar's compensation has been consistent with company performance over the past year.

CEO

Shankar Musunuri (59 yo)

4.4yrs

Tenure

US$7,662,810

Compensation

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Principal Financial Off...

Leadership Team

NamePositionTenureCompensationOwnership
Shankar Musunuri
Co-Founder4.4yrsUS$7.66m0.80%
€ 1.9m
Uday Kompella
Co-founder & Independent Directorno dataUS$341.82k0.27%
€ 643.6k
Michael Breininger
Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controllerless than a yearno datano data
Arun Upadhyay
Chief Scientific Officer and Head of Research & Development1.4yrsno data0.041%
€ 95.4k
John Kouch
General Counselno datano datano data
Tiffany Hamilton
Head of Corporate Communicationsno datano datano data
Michael Shine
Senior Vice President of Commercial2.7yrsno datano data
Jyothy Pillai
Head of Regulatory & Qualityless than a yearno datano data

1.4yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 2H51's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Shankar Musunuri
Co-Founder4.4yrsUS$7.66m0.80%
€ 1.9m
Uday Kompella
Co-founder & Independent Director4.4yrsUS$341.82k0.27%
€ 643.6k
Prabhavathi Fernandes
Independent Director3.8yrsUS$357.60k0%
€ 0
Carl Regillo
Member of Retina Scientific Advisory Board4.3yrsno datano data
Ramesh Kumar
Independent Director4.4yrsUS$347.28k0%
€ 0
David Boyer
Member of Retina Scientific Advisory Boardno datano datano data
Bruce Forrest
Vaccine Scientific Advisory Board Member3.2yrsno datano data
Junge Zhang
Independent Director4.4yrsUS$335.56k0.45%
€ 1.1m
Geeta Lalwani
Member of Retina Scientific Advisory Boardno datano datano data
Kirsten Castillo
Independent Director3.8yrsUS$348.18k0.019%
€ 45.6k
Satishchandran Chandrasekhar
Vaccine Scientific Advisory Board Member3.2yrsno datano data
Mark Pennesi
Member of Retina Scientific Advisory Board4.3yrsno datano data

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: 2H51's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/28 19:43
End of Day Share Price 2023/12/01 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocugen, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Daniil GataulinChardan Capital Markets, LLC
Swayampakula RamakanthH.C. Wainwright & Co.